In this study, we selected 58
styrene-exposed workers, measured personal styrene exposure, evaluated genotypes
relevant drug-metabolizing enzymes (CYP2E1, EPHX1, GSTM1 and GSTT1) which may
explain the variability in the urinary metabolite excretion. The results showed
that, in different levels of styrene exposure groups, there is a significant association
between urinary metabolites and some genotypes of styrene-metabolizing enzymes,
including CYP2E1 (5-flanking region, RsaI/PstI), GSTM1(gene deletions) and EPHX1(predicted
activity).
[1]
Sarmaovvá, J., Tynková, L., Süsová, S., Cut, I. and Soucek, P. (2000) Genetic Polymorphisms of Biotransformation Enzymes: Allele Frequencies in the Population of Czech Republic. Pharmacogenetics, 10, 781-788.
http://dx.doi.org/10.1097/00008571-200012000-00003
[2]
VeMina, A, Galati, R., Falasca, G., et al. (2001) Metabolic Polymorphisms and Urinary Biomarkers in Subjects with Low Benzene Exposure. Journal of Toxicology and Environmental Health, 64, 607-618.
http://dx.doi.org/10.1080/152873901753246214
[3]
Kim, H., Wang, R.S., Elovaara, E., et al. (1997) Cytochrome P450 Isoenzymes Responsible for the Metabolism of Toluene and Styrene in Human Liver Microsomes. Xenobiotica, 27, 657-665.
http://dx.doi.org/10.1080/004982597240253
